All In Biotech

NDA 018163 · Specgx LLC

Restoril

Temazepam · Oral · Benzodiazepine

Novel

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Feb 27, 1981

Approved uses

3

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 0 recruiting

FAERS reports

37,909

28,415 serious, 7,674 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation ( see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including temazepam capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...

What it is approved for

From the label in effect Oct 6, 2026.

INDICATIONS AND USAGE Temazepam Capsules USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules USP should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • RESTORIL · TEMAZEPAM 22.5MG · CAPSULE, ORAL · Prescription · TE AB
  • RESTORIL · TEMAZEPAM 30MG · CAPSULE, ORAL · Prescription · TE AB
  • RESTORIL · TEMAZEPAM 7.5MG · CAPSULE, ORAL · Prescription · TE AB
  • RESTORIL · TEMAZEPAM 15MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Temazepam" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,856
  • drug ineffective2,480
  • nausea2,454
  • pain2,332
  • headache2,331
  • toxicity to various agents2,306
  • diarrhoea1,841
  • dyspnoea1,792
  • insomnia1,707
  • death1,701
  • dizziness1,691
  • off label use1,683

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004841
2005965
20061,079
2007922
2008924
20091,231
20101,588
20111,536
20121,790
20131,473
20141,664
20152,614
20162,850
20172,573
20182,626
20192,570
20202,378
20211,862
20221,352
20231,427
20241,528
20251,173
2026941

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Restoril (Temazepam)

2024 spending

$713K

Beneficiaries

105

470 claims

Per beneficiary

$6,790

$30.62 per unit

View as table
YearSpending
2020$1,423,306
2021$1,385,243
2022$1,209,060
2023$983,605
2024$712,925

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 265 on PubMed

Sponsor: Specgx LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.